Econ Financial Services Corp Purchases Shares of 25,590 Pfizer Inc. $PFE

Econ Financial Services Corp purchased a new stake in Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 25,590 shares of the biopharmaceutical company’s stock, valued at approximately $637,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Horizon Financial Services LLC lifted its position in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares during the last quarter. Grey Fox Wealth Advisors LLC acquired a new stake in Pfizer in the third quarter valued at approximately $29,000. Howard Hughes Medical Institute purchased a new position in Pfizer in the second quarter worth $30,000. Darwin Wealth Management LLC purchased a new position in Pfizer in the second quarter worth $32,000. Finally, True Wealth Design LLC increased its position in shares of Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 974 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Fresh real‑world data from Pfizer’s Swedish observational study on Ibrance (palbociclib) is being framed as a positive signal for the drug’s real‑world effectiveness and market durability, which could support oncology revenue expectations. Pfizer’s Swedish Ibrance Study
• Positive Sentiment: Heightened media and retail investor attention around Pfizer’s GLP‑1/weight‑loss pipeline (including coverage noting share strength despite a high‑profile “pass” comment) is boosting sentiment—investors are pricing potential upside from a once‑monthly treatment. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: Dividend appeal remains a tailwind for income investors—Pfizer is regularly cited among large caps with attractive dividends, supporting buy‑and‑hold interest. Pfizer – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Retail and institutional attention is elevated (high search/coverage), which can amplify moves but doesn’t guarantee direction — monitor whether flow sustains. Investors Heavily Search Pfizer Inc. (PFE)
• Neutral Sentiment: Broader sector moves (e.g., large deals and AI partnerships at peers) are reshaping investor rotation in healthcare but are not direct Pfizer catalysts; they do, however, affect relative valuation dynamics. Eli Lilly Ramps Up AI Ambitions
• Negative Sentiment: Fundamentals still carry risk: quarterly revenue was slightly down year‑over‑year even as EPS beat estimates, and Pfizer faces stiff competition in the GLP‑1/weight‑loss space from larger early movers—both could cap upside if execution or pricing weakens.

Pfizer Trading Up 1.1%

NYSE:PFE opened at $28.08 on Wednesday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $28.31. The firm has a fifty day simple moving average of $26.94 and a 200-day simple moving average of $25.75. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $159.67 billion, a P/E ratio of 20.65 and a beta of 0.47.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm’s revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.63 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on PFE shares. Barclays assumed coverage on Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective for the company. BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 target price on shares of Pfizer in a research report on Monday, March 9th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, February 4th. UBS Group started coverage on Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target for the company. Finally, Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $28.19.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.